The Testosterone Project Launches on National Testosterone Awareness Day, November 17
15 nov. 2024 09h49 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Nov. 15, 2024 (GLOBE NEWSWIRE) -- The Testosterone Project, a new nonprofit founded by leading experts in the fields of testosterone treatment and general metabolic health, launches...
New Data from Marius Pharmaceuticals Reveals High Prevalence of Low Libido, Energy and Quality of Life in Men
14 nov. 2024 09h30 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, has released compelling new...
KYZATREX® (testosterone undecanoate) CIII Capsules Featured in Research at the Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
16 oct. 2024 09h00 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals is pleased to announce that KYZATREX® (testosterone undecanoate) CIII capsules will be highlighted in three research abstracts...
Marius Pharmaceuticals Partners with UK-Based Numan to Combat Testosterone Deficiency with KYZATREX® (Testosterone Undecanoate) CIII Capsules
18 sept. 2024 09h00 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals is pleased to announce a new partnership with Numan, a leading UK-based, VC-backed digital health platform, to introduce...
Marius Pharmaceuticals Submits KYZATREX® (Testosterone Undecanoate) CIII Capsules for Approval to Health Canada
30 juil. 2024 09h30 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focused on developing innovative therapies for Testosterone Deficiency, is pleased to...
Marius Pharmaceuticals Expands Access of KYZATREX™ (testosterone undecanoate) to Department of Veterans Affairs (VA), Pledging Support for Proper Hormonal Balance Among Military Personnel
19 sept. 2023 09h30 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, is proud to announce the...
Marius Pharmaceuticals Partners with Smartway to Design and Manage the global Early Access Program for KYZATREX™ (testosterone undecanoate)
10 août 2023 09h30 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals (Marius) and Smartway Pharmaceuticals (Smartway) are pleased to announce their strategic partnership, aimed at addressing the...
Marius Pharmaceuticals Announces Launch of ReThink Testosterone, Disease-State Awareness Initiative for Patients
24 juil. 2023 09h00 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., July 24, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or Testosterone Deficiency, is proud to...
Marius Pharmaceuticals Supports AXYS 2023 Virtual Family Conference, Spotlighting KYZATREX™ for XY Chromosome Variations, such as Klinefelter’s Syndrome
20 juin 2023 08h30 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., June 20, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or testosterone deficiency, announced today...
Marius Pharmaceuticals Announces Two Key Patents Related to KYZATREX™ in FDA Orange Book
09 juin 2023 10h00 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., June 09, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focused on therapies designed for hypogonadism or testosterone deficiency, announced...